BioRestorative Therapies, Inc.
BRTXNASDAQHealthcare● Active
$0.39
+$0.02(+6.80%)
Market Cap$3476501
P/E Ratio—
52W High$2.045
52W Low$0.1593
BioRestorative Therapies, Inc. (BRTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BRTX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.36M | $0.40M | $0.15M | $0.12M | $0.05M |
| Cost of Revenue | $0.02M | $0.03M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.34M | $0.37M | $0.15M | $0.12M | $0.05M |
| Gross Margin %(computed) | 93.37% | 93.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $10.09M | $5.35M | $4.03M | $3.51M | $0.73M |
| G&A Expenses | $5.89M | $6.58M | $11.33M | $15.58M | $25.62M |
| Total Operating Expenses | $15.98M | $11.93M | $15.37M | $18.98M | $26.35M |
| Operating Income | ($15.65M) | ($11.56M) | ($15.22M) | ($18.86M) | ($26.31M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.27M | $0.62M | $0.55M | $0.01M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $1.82M |
| Income Before Tax | ($14.24M) | ($8.98M) | ($10.42M) | ($13.22M) | ($44.30M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($14.24M) | ($8.98M) | ($10.42M) | ($13.22M) | ($44.30M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.58 | $-1.16 | $-2.47 | $-3.65 | $-37.30 |
| Wtd Avg Shares | 8.99M | 7.76M | 4.22M | 3.62M | 1.19M |
| EBITDA | ($15.44M) | ($11.37M) | ($14.97M) | ($18.74M) | ($26.22M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more BioRestorative Therapies, Inc. data
About BioRestorative Therapies, Inc. (BRTX) Income Statement
BioRestorative Therapies, Inc. (BRTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BRTX reported revenue of $0.00B, gross profit of $0.00B (gross margin 93.37%), and net income of ($0.01B) — a net profit margin of -3959.40%.
Frequently asked questions
BRTX · 4 questionsBioRestorative Therapies, Inc. (BRTX) reported revenue of $0.00B for 2025, down 10.3% year-over-year.
BRTX revenueBRTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09